Subject(s)
Patient Readmission , Pressure Ulcer/nursing , Adult , Aged , Female , Humans , Male , Middle Aged , Outcome and Process Assessment, Health Care , Patient Compliance , Patient Education as Topic , RecurrenceABSTRACT
Beta-adrenergic blocking drugs are gaining acceptance as initial therapy for patients with mild to moderate hypertension. In a postmarketing surveillance study, 5,190 hypertensive patients received timolol maleate monotherapy and were evaluated by 1,355 physicians. A total of 1,057 patients did not complete the study: 28% of these patients experienced an adverse event. Mean systolic and diastolic blood pressure readings were reduced 20 and 13 mm Hg, respectively. Mean diastolic blood pressure was reduced 11% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (17%) and severe hypertension (22%). The effect in black and elderly patients was less than in other groups. Although 22% of all patients experienced an adverse event, less than 2.2% of all patients experienced events related to beta-adrenergic blockade, ie, respiratory difficulty, heart failure, bradycardia, and cold extremities. Fatigue, dizziness, and nausea were the most frequently reported adverse events requiring discontinuation of therapy. Timolol monotherapy is a well-tolerated and effective treatment for a broad range of hypertensive patients.
Subject(s)
Hypertension/drug therapy , Timolol/therapeutic use , Adult , Aged , Blood Pressure/drug effects , Female , Follow-Up Studies , Humans , Hypertension/physiopathology , Male , Middle Aged , Pulse/drug effects , Timolol/adverse effectsABSTRACT
Chest roentgenograms of 152 patients with type 2/3 disease observed 3 or more years were reviewed using modified ILO/UC nomenclature. After a mean length of observation of 9.3 years, clinical recovery was observed in 71.7% and radiologic recovery in 48.0% of the patients. Age; duration of observation; mediastinal adenopathy; and character (xyz, pgr, stu), size, extent, and profusion of pulmonary densities were similar in the 53 white and 99 black patients, who differed significantly only in sex distribution. White patients achieved clinical recovery (84.9%) more often than black patients (64.7%) (p = .05). Factors influencing clinical recovery were analyzed by means of stepwise logistic linear regression. The initial roentgenographic features were unrelated to outcome; only race and extrathoracic disease proved to have significant predictive value. The probability of clinical recovery is estimated to be .894 in white patients with disease limited to the chest, .697 in white patients with extrathoracic disease, and .760 in black patients without and .454 in black patients with extrathoracic sarcoidosis. Recovery appears to be related not to the severity of the initial pulmonary reaction but to racially associated factors that influence extrathoracic dissemination as well as lung damage.
Subject(s)
Lung Diseases/diagnostic imaging , Lung/diagnostic imaging , Sarcoidosis/diagnostic imaging , Adult , Black People , Female , Follow-Up Studies , Humans , Lung Diseases/mortality , Male , Prognosis , Radiography , Sarcoidosis/mortality , Time Factors , White PeopleABSTRACT
A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients. Data on 9,037 patients were collected by 1,455 participating physicians. Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol-hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and weakness. Treatment in 590 patients was discontinued because of adverse events.
